checkAd

     236  0 Kommentare Novartis announces plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program - Seite 4

    Please see full Prescribing Information available at www.jakavi.com.

    Disclaimer
    This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “suggests,”“pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Jakavi, regarding potential future revenues from such products, regarding our plans to initiate a clinical trial to evaluate the use of Jakavi in severe COVID-19 patients, or regarding the international compassionate use program for eligible patients. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Jakavi will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that we will initiate the planned clinical trial in the expected time frame, or at all. Nor can there be any guarantee that Jakavi will meet the primary or any secondary endpoints of the planned trial. Neither can there be any guarantee that Jakavi will be commercially successful in the future. In particular, our expectations regarding such products and the international compassionate use program could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

    Seite 4 von 6



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Novartis announces plan to initiate clinical study of Jakavi in severe COVID-19 patients and establish international compassionate use program - Seite 4 New clinical trial to evaluate Jakavi (ruxolitinib) in patients with COVID-19 associated cytokine storm  Cytokine storm is a type of severe immune overreaction that can result from coronavirus infection and may contribute to respiratory compromise …

    Schreibe Deinen Kommentar

    Disclaimer